title: In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
abstract: Ceftazidime and amikacin were administered in a Pseudomonas aeruginosa rabbit endocarditis model using computer-controlled intravenous (iv) infusion pumps to simulate human serum concentrations for the following regimens: continuous (constant rate) infusion of 4, 6 or 8 g of ceftazidime over 24 h or intermittent dosing of 2 g every 8 h either alone or in combination with amikacin (15 mg/kg once daily). The in vivo activities of these regimens were tested on four Pseudomonas aeruginosa strains. Animals were killed 24 h after the beginning of treatment. Efficacy was assessed by comparing the effects of the different groups on bacterial counts in vegetations for each strain tested. For a susceptible reference strain (ATCC 27853; MICs of ceftazidime and amikacin 1 and 2 mg/L, respectively), continuous infusion of 4 g alone or with amikacin was as effective as intermittent dosing with amikacin. For a clinical isolate producing an oxacillinase (MICs of ceftazidime and amikacin 8 and 32 mg/L, respectively), continuous infusion of 6 g was equivalent to intermittent dosing. For a clinical isolate producing a TEM-2 penicillinase (MIC of ceftazidime and amikacin 4 mg/L), continuous infusion of 6 g, but not intermittent dosing, had a significant in vivo effect. For a clinical isolate producing an inducible, chromosomally encoded cephalosporinase (MIC of ceftazidime and amikacin 8 and 4 mg/L, respectively), neither continuous infusion nor intermittent dosing proved effective. Determination of ceftazidime concentrations in vegetations showed that continuous infusion produced tissue concentrations at the infection site far greater than the MIC throughout the treatment. It is concluded that continuous infusion of the same total daily dose provides significant activity as compared with fractionated infusion. This study confirms that a concentration of 4-5 x MIC is a reasonable therapeutic target in most clinical settings of severe P. aeruginosa infection.
authors.affiliation: Laboratoire d'Antibiologie Clinique et Expérimentale, Faculté de Médecine, 1 rue Gaston-Veil, 44035 Nantes, France.
authors.forename: M A
authors.initials: MA
authors.lastname: Robaux
authors.forename: L
authors.initials: L
authors.lastname: Dube
authors.forename: J
authors.initials: J
authors.lastname: Caillon
authors.forename: D
authors.initials: D
authors.lastname: Bugnon
authors.forename: M F
authors.initials: MF
authors.lastname: Kergueris
authors.forename: D
authors.initials: D
authors.lastname: Navas
authors.forename: P
authors.initials: P
authors.lastname: Le Conte
authors.forename: D
authors.initials: D
authors.lastname: Baron
authors.forename: G
authors.initials: G
authors.lastname: Potel
mesh_terms: D000583:Amikacin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002442:Ceftazidime / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002511:Cephalosporins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D007700:Kinetics; D008826:Microbial Sensitivity Tests; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D011817:Rabbits
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000583:Amikacin; D002442:Ceftazidime